NASDAQ:DBTX

Decibel Therapeutics (DBTX) Stock Forecast, Price & News

$5.03

+2.24 (+80.29%)

(As of 08/9/2023 ET)

Compare

Today's Range: $4.73
▼
$5.09
50-Day Range: $2.76
▼
$4.81
52-Week Range: $1.61
▼
$5.68

Volume: 6.02 million shs
Average Volume: 96,050 shs
Market Capitalization: $125.83 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $9.25

Decibel Therapeutics MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.50 Rating Score
Upside/Downside: 83.9% Upside
$9.25 Price Target
Short Interest: Healthy
0.67% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: -0.45
Based on 7 Articles This Week
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.62) to ($1.08) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.26 out of 5 stars

Medical Sector

330th out of 970 stocks

Pharmaceutical Preparations Industry

145th out of 456 stocks

3.1

Analyst's Opinion

Consensus Rating
Decibel Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $9.25, Decibel Therapeutics has a forecasted upside of 83.9% from its current price of $5.03.
Amount of Analyst Coverage
Decibel Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.67% of the float of Decibel Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Decibel Therapeutics has a short interest ratio ("days to cover") of 3, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Decibel Therapeutics has recently decreased by 27.58%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Decibel Therapeutics does not currently pay a dividend.
Dividend Growth
Decibel Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for DBTX.

1.4

News and Social Media Coverage

News Sentiment
Decibel Therapeutics has a news sentiment score of -0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.42 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 7 news articles for Decibel Therapeutics this week, compared to 1 article on an average week.
Search Interest
2 people have searched for DBTX on MarketBeat in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Decibel Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
35.60% of the stock of Decibel Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
61.79% of the stock of Decibel Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Decibel Therapeutics are expected to grow in the coming year, from ($1.62) to ($1.08) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Decibel Therapeutics is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Decibel Therapeutics is -2.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Decibel Therapeutics has a P/B Ratio of 1.53. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Decibel Therapeutics (NASDAQ:DBTX) Stock

Decibel Therapeutics, Inc., a clinical-stage biotechnology company, engages in discovering and developing transformative treatments for hearing and balance disorders. The company's product candidates and programs focuses on three areas, such as Gene Therapies for Congenital, Monogenic Hearing Loss designed to restore functional cells within the cochlea to address hearing disorders caused by single gene mutations; Gene Therapies for Hair Cell Regeneration designed to replace lost hair cells within the inner ear to address acquired hearing loss and balance disorders; and Otoprotection Therapeutic in clinical development to prevent hearing loss in cancer patients undergoing chemotherapy with cisplatin. Its lead gene therapy product candidate is DB-OTO to provide hearing to individuals born with profound hearing loss due to mutation of the otoferlin gene. The company is also developing DB-ATO and AAV.201, a gene therapy program designed to restore balance in patients with bilateral vestibulopathy by regenerating lost hair cells within the vestibule; DB-020 for the prevention of cisplatin-induced hearing loss, which is in Phase 1b clinical trial; AAV.103 to restore hearing in individuals with a gap junction beta-2 (GJB2) deficiency; AAV.104 to restore hearing in individuals with stereocilin (STRC) deficiency; and cochlear hair cell regeneration program, an AAV-based gene therapy that utilizes cell-selective expression of reprogramming factors to convert supporting cells into outer hair cells. Decibel Therapeutics, Inc. has a strategic collaboration with Regeneron Pharmaceuticals, Inc. to develop gene therapies for monogenic forms of congenital hearing loss. The company was formerly known as Hearing Inc. and changed its name to Decibel Therapeutics, Inc. in April 2014. Decibel Therapeutics, Inc. was incorporated in 2013 and is headquartered in Boston, Massachusetts.

DBTX Price History

30 days | 90 days | 365 days | Advanced Chart

DBTX Stock News Headlines

August 9, 2023 | washingtonpost.com

Complaints about airplane noise rise at Reagan National, Dulles

August 9, 2023 | msn.com

Regeneron to acquire gene therapy developer Decibel for $4 per share

August 10, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.

August 9, 2023 | msn.com

Decibel Therapeutics (NASDAQ:DBTX) Skyrockets On Acquisition By Regeneron

August 9, 2023 | benzinga.com

Shareholder Alert: Ademi LLP investigates whether Decibel Therapeutics, Inc. has obtained a Fair Price in its transaction with Regeneron

August 9, 2023 | finance.yahoo.com

Regeneron to Acquire Decibel Therapeutics, Strengthening Gene Therapy and Hearing Loss Programs

July 21, 2023 | finance.yahoo.com

DBTX - Decibel Therapeutics, Inc.

June 22, 2023 | markets.businessinsider.com

Robert W. Baird Reaffirms Their Buy Rating on Decibel Therapeutics (DBTX)

August 10, 2023 | Behind the Markets (Ad)

BREAKING: Tiny biotech successfully treats blindness

June 6, 2023 | markets.businessinsider.com

H.C. Wainwright Reaffirms Their Buy Rating on Decibel Therapeutics (DBTX)

June 2, 2023 | finance.yahoo.com

Decibel Therapeutics to Participate in the Upcoming Jefferies Healthcare Conference

June 1, 2023 | finance.yahoo.com

Decibel Therapeutics to Present DB-020 Phase 1b Clinical Trial Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting

May 29, 2023 | markets.businessinsider.com

SVB Securities Sticks to Its Hold Rating for Decibel Therapeutics (DBTX)

May 17, 2023 | finance.yahoo.com

Decibel Therapeutics to Participate in the Upcoming Barclays 2023 Gene Editing and Gene Therapy Summit

May 15, 2023 | finance.yahoo.com

Decibel Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update

May 13, 2023 | msn.com

HC Wainwright & Co. Reiterates Decibel Therapeutics (DBTX) Buy Recommendation

May 12, 2023 | finance.yahoo.com

Decibel Therapeutics Announces Approval of Clinical Trial Application by the Spanish Agency of Medicines and Medical Devices (AEMPS) to Initiate Clinical Development of Lead Gene Therapy Candidate DB-OTO

May 10, 2023 | forbes.com

Db Insurance

May 10, 2023 | finance.yahoo.com

Decibel Therapeutics to Present at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting

March 30, 2023 | finance.yahoo.com

Decibel Therapeutics Receives European Orphan Drug Designation for Lead Gene Therapy Candidate DB-OTO

March 28, 2023 | finance.yahoo.com

Decibel Therapeutics to Participate in the Upcoming Guggenheim Healthcare Talks | Genomic Medicines and Rare Disease Days

March 21, 2023 | finance.yahoo.com

Decibel Therapeutics Appoints Matthew Kapusta to its Board of Directors

March 19, 2023 | finanznachrichten.de

Decibel Therapeutics, Inc.: Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

March 16, 2023 | msn.com

SVB Leerink Downgrades Decibel Therapeutics (DBTX)

March 14, 2023 | finance.yahoo.com

Decibel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Corporate Update

March 2, 2023 | finance.yahoo.com

private equity firms who own 39% along with institutions invested in Decibel Therapeutics, Inc. (NASDAQ:DBTX) saw increase in their holdings value last week

February 16, 2023 | finance.yahoo.com

Decibel Therapeutics to Present at the Upcoming SVB Securities Global Biopharma Conference

See More Headlines

Receive DBTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Decibel Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

DBTX Company Calendar

Last Earnings: 5/15/2023
Today: 8/09/2023
Next Earnings (Estimated): 8/09/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:DBTX
CUSIP: N/A
CIK: 1656536
Web: decibeltx.com
Phone: 617-370-8701
Fax: N/A
Employees: 68
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $9.25
High Stock Price Forecast: $23.00
Low Stock Price Forecast: $2.00
Forecasted Upside/Downside: +83.9%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($2.48)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-63,010,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -69.15%
Return on Assets: -46.63%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.14
Quick Ratio: 4.14

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.28 per share
Price / Book: 1.53

Miscellaneous

Outstanding Shares: 25,010,000
Free Float: 16,110,000
Market Cap: $125.80 million
Optionable: Not Optionable
Beta: -0.20

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Key Executives

Dr. Laurence E. Reid Ph.D. (Age 59)
Pres, CEO & Director
Comp: $742.98k

Ms. Anna Trask M.A. (Age 65)
Exec. VP & Chief People Officer
Comp: $481.23k

Mr. John J. Lee (Age 55)
Exec. VP & Chief Devel. Officer
Comp: $596.15k

Mr. M. Charles Liberman
Co-Founder & Member of Scientific Advisory Board

Dr. Gabriel Corfas
Co-Founder & Member of Scientific Advisory Board

Dr. Ulrich Müller
Co-Founder & Member of Scientific Advisory Board

Dr. Albert S. B. Edge (Age 68)
Co-Founder & Member of Scientific Advisory Board

Mr. James B. Murphy (Age 66)
Interim CFO, Principal Financial Officer & Principal Accounting Officer

Ms. Elaine Cope M.B.A.
VP of Operations

Mr. Geoff Horwitz
VP of Corp. Devel. & Head of Bus. Devel.

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions

DBTX Stock - Frequently Asked Questions

Should I buy or sell Decibel Therapeutics stock right now?: 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Decibel Therapeutics in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "hold" DBTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in DBTX, but not buy additional shares or sell existing shares.
View DBTX analyst ratings or view top-rated stocks.
What is Decibel Therapeutics' stock price forecast for 2023?: 4 brokerages have issued twelve-month price objectives for Decibel Therapeutics' stock. Their DBTX share price forecasts range from $2.00 to $23.00. On average, they anticipate the company's stock price to reach $9.25 in the next twelve months. This suggests a possible upside of 83.9% from the stock's current price.
View analysts price targets for DBTX or view top-rated stocks among Wall Street analysts.
How have DBTX shares performed in 2023?: Decibel Therapeutics' stock was trading at $2.05 at the start of the year. Since then, DBTX shares have increased by 145.4% and is now trading at $5.03.
View the best growth stocks for 2023 here.
Are investors shorting Decibel Therapeutics?: Decibel Therapeutics saw a decrease in short interest in the month of July. As of July 15th, there was short interest totaling 82,700 shares, a decrease of 27.6% from the June 30th total of 114,200 shares. Based on an average daily trading volume, of 27,600 shares, the days-to-cover ratio is presently 3.0 days. Approximately 0.7% of the shares of the stock are short sold.
View Decibel Therapeutics' Short Interest.
When is Decibel Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 9th 2023.
View our DBTX earnings forecast.
How were Decibel Therapeutics' earnings last quarter?: Decibel Therapeutics, Inc. (NASDAQ:DBTX) announced its quarterly earnings results on Monday, May, 15th. The company reported ($0.53) earnings per share for the quarter, missing analysts' consensus estimates of ($0.48) by $0.05.

When did Decibel Therapeutics IPO?: (DBTX) raised $100 million in an initial public offering on Friday, February 12th 2021. The company issued 5,900,000 shares at a price of $16.00-$18.00 per share. Citigroup, BMO Capital Markets, SVB Leerink and Barclays served as the underwriters for the IPO.
What is Decibel Therapeutics' stock symbol?: Decibel Therapeutics trades on the NASDAQ under the ticker symbol "DBTX."
Who are Decibel Therapeutics' major shareholders?: Decibel Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Bailard Inc. (0.04%). Insiders that own company stock include Anna Trask, Casdin Partners Master Fund, L, Laurence Reid and Plc Glaxosmithkline.
View institutional ownership trends.
How do I buy shares of Decibel Therapeutics?: Shares of DBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Decibel Therapeutics' stock price today?: One share of DBTX stock can currently be purchased for approximately $5.03.
How much money does Decibel Therapeutics make?: Decibel Therapeutics (NASDAQ:DBTX) has a market capitalization of $125.80 million. The company earns $-63,010,000.00 in net income (profit) each year or ($2.48) on an earnings per share basis.
How can I contact Decibel Therapeutics?: Decibel Therapeutics' mailing address is 1325 Boylston Street Suite 500, Boston MA, 02215. The official website for the company is decibeltx.com. The company can be reached via phone at 617-370-8701 or via email at ir@decibeltx.com.

This page (NASDAQ:DBTX) was last updated on 8/10/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial